Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Bought by Erste Asset Management GmbH

Erste Asset Management GmbH raised its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 11.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 708,248 shares of the biotechnology company’s stock after acquiring an additional 72,183 shares during the quarter. Sarepta Therapeutics accounts for about 1.0% of Erste Asset Management GmbH’s portfolio, making the stock its 16th biggest holding. Erste Asset Management GmbH’s holdings in Sarepta Therapeutics were worth $86,116,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. CIBC Asset Management Inc lifted its stake in Sarepta Therapeutics by 3.3% during the third quarter. CIBC Asset Management Inc now owns 2,712 shares of the biotechnology company’s stock valued at $339,000 after buying an additional 86 shares in the last quarter. Louisiana State Employees Retirement System lifted its stake in Sarepta Therapeutics by 0.4% during the fourth quarter. Louisiana State Employees Retirement System now owns 26,500 shares of the biotechnology company’s stock valued at $3,222,000 after buying an additional 100 shares in the last quarter. Manchester Capital Management LLC lifted its stake in Sarepta Therapeutics by 86.6% during the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 110 shares in the last quarter. UMB Bank n.a. lifted its stake in Sarepta Therapeutics by 36.0% during the fourth quarter. UMB Bank n.a. now owns 521 shares of the biotechnology company’s stock valued at $63,000 after buying an additional 138 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. lifted its stake in Sarepta Therapeutics by 3.4% during the third quarter. Oppenheimer Asset Management Inc. now owns 4,457 shares of the biotechnology company’s stock valued at $557,000 after buying an additional 145 shares in the last quarter. 86.68% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

SRPT has been the subject of a number of analyst reports. Piper Sandler reduced their price objective on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a research note on Wednesday, November 27th. StockNews.com lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. Scotiabank started coverage on Sarepta Therapeutics in a report on Friday, March 7th. They issued a “sector perform” rating and a $105.00 target price on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $202.00 target price on shares of Sarepta Therapeutics in a report on Thursday, February 27th. Finally, Deutsche Bank Aktiengesellschaft started coverage on Sarepta Therapeutics in a report on Tuesday, February 11th. They issued a “hold” rating and a $136.00 target price on the stock. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $170.41.

Sarepta Therapeutics Trading Down 0.9 %

NASDAQ:SRPT opened at $99.77 on Thursday. Sarepta Therapeutics, Inc. has a 12 month low of $97.91 and a 12 month high of $173.25. The firm has a market cap of $9.68 billion, a price-to-earnings ratio of 79.82 and a beta of 0.79. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The company’s 50 day moving average is $112.83 and its 200-day moving average is $120.55.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.